Drug intelligence / Profile preview

NEO-STIM

Development stage: Unknown
Lead developer: BioNTech
Modality: Cell Therapies
Administration: Intravenous

Overview

NEO-STIM is a proprietary ex-vivo T cell induction and expansion platform developed by Neon Therapeutics (now part of BioNTech). It is designed to identify, prime, and expand patient-specific T cells targeting tumor neoantigens. The process utilizes the RECON bioinformatics engine to predict high-quality neoantigens, which are then used in the NEO-STIM protocol to activate both CD4+ and CD8+ T cell responses from a patient's peripheral blood mononuclear cells (PBMCs). This platform serves as a manufacturing process for personalized adoptive cell therapies, such as NEO-PTC-01 (now BNT221), intended for the treatment of various solid tumors, including melanoma and non-small cell lung cancer (NSCLC).

Brand names: NEO-STIM

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on NEO-STIM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEO-STIM.

Explore the full profile